C199
C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity.
(Pink: PRMT4 ligand (HY-111109); Blue: VHL ligand (HY-112078); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3107801-96-4
- Formula: C67H95ClN10O8S
- Molecular Weight:1236.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
VHL |
PRMT4 |
In Vitro
C199 (Compound C199) (0.001-1 μM, 12 days) potently inhibits myeloma cell proliferation[1].
C199 (0.007-0.5 μM, 6 days) induces dose-dependent apoptosis in NCI-H929 cells[1].
C199 (0.01-0.5 μM, 12-72 h) efficiently and selectively degrades PRMT4 protein in NCI-H929 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NCI-H929 cells
-
Concentration:0.007 μM, 0.031 μM, 0.062 μM, 0.125 μM, 0.5 μM
-
Incubation Time:6 days
-
Result:Apoptosis rates prominently reached 81.9% at 0.5 μM.
-
Cell Line:NCI-H929 cells
-
Concentration:0.01 μM, 0.03 μM, 0.06 μM, 0.1 μM, 0.12 μM, 0.25 μM, 0.5 μM
-
Incubation Time:12 h, 24 h, 48 h, 72 h
-
Result:Reached a degradation efficiency of 92 % when the compound concentration was 0.5 μM.
Still maintained a high degradation efficiency of 56 % when the concentration dropped to 0.1 μM.
Had a DC50 of 0.106 μM, caused a significant decrease in PRMT4 level by about half after 24 hours, and reached a Dmax of 93.1 % after 72 hours.
Degraded PRMT4 via a VHL- and proteasome-dependent instead of lysosomal pathway.
Inhibited PABP1 methylation by 97 %, while EZM2302 only inhibited 37 %. Was about three times more efficient than EZM2302 in inhibiting BAF155 methylation.
Affected only the expression of PRMT4 and had no effect on other homologous proteins.
Effectively modulated asymmetric dimethylation of PRMT4 substrates through targeted degradation of the methyltransferase.
-
Cell Line:NCI-H929 cells, RPMI-8226 cells
-
Concentration:0.001 μM, 0.01 μM. 0.1 μM, 1 μM
-
Incubation Time:12 days
-
Result:Outperformed the inhibitor EZM2302 significantly (GI50: 0.089 μM for NCI-H929 cells, 0.145 μM for RPMI-8226 cells).
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | AUClast |
|---|---|---|---|---|---|
| Mice | 10 mg/kg | p.o. | 0.08 h | 255.33 ng/mL | 3843.67 ng·h/mL |
| Mice | 2 mg/kg | i.v. | 0.08 h | 661.33 ng/mL | 7812.14 ng·h/mL |
In Vivo
C199 (Compound C199) (40-80 mg/kg, i.p, twice daily for 20 days) inhibits the growth of multiple myeloma xenografts and downregulated the expression of PRMT4 in BALB/c nude mice without obvious organ toxicity[1].
C199 (100-1000 mg/kg, i.p, once daily for 14 days) has good safety at high doses in CD1 mice, a wide therapeutic window, and excellent safety[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-H929 xenograft model established in female BALB/c nude mice (6-8 weeks, 18-22 g)[1]
-
Dosage:40 mg/kg, 80 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice daily for 20 days
-
Result:Inhibited tumor growth (TGI = 78 %).
Significantly reduced tumor PRMT4 protein.
Left the heart, liver, spleen and kidneys morphologically normal.
-
Animal Model:Famale and male CD1 nude mice[1]
-
Dosage:100 mg/kg, 500 mg/kg, 1000 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 14 days
-
Result:Left body weight and organ indexes normal, and caused no death or organ damage at 1000 mg/kg.
Chemical Information
-
CAS No. 3107801-96-4
-
Molecular Weight 1236.05
-
Formula C67H95ClN10O8S
-
SMILES
O=C(N[C@H](C1=CC=C(C=C1)C2=C(N=CS2)C)C)[C@H]3N(C[C@@H](C3)O)C([C@H](C(C)(C)C)NC(CCCCCCCCCCCCCCCC(N4CCC5(CN(C5)C6=NC(C7=CC(OC[C@@H](CNC)O)=CC=C7Cl)=NC(C8=C(ON=C8C)C)=C6C)CC4)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)